Amgen CEO Robert A. Bradway discusses the potential impact of the election, and politics in general, will have on the industry.

At the Financial Times’ Global Pharma and Biotech Summit 2024, Christophe Weber, president and CEO, Takeda, discusses how trust and collaboration between the biopharma industry and stakeholders can be implemented to support successful healthcare transformation.

Ron Lanton, Partner, Lanton Law, discusses the legal implications of the FDA’s broad label challenge to PD-1 inhibitors for gastric cancers.

Abi Carter is timing the partnership with the release of her upcoming album.

The healthcare company signed a deal with Infirmary Health, who services customers in Georgia and parts of Florida and Mississippi.

The latest news for pharma industry insiders.

Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab discusses the need to balance personalized targeting with the ethical imperative to protect consumer privacy.

Results from the VENTURE Phase II trial and a Phase I oral formulation study found that VK2735, a novel a dual GLP-1 and GIP receptor agonist, demonstrated promise in treating obesity.

Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab explores the most promising alternative targeting methods that advertisers can adopt in a post-cookie world, and how they compare to traditional approaches.

The latest news for pharma industry insiders.

Results from Part I of the Phase III ESSENCE trial found that Wegovy 2.4 mg achieved a 37% improvement in liver fibrosis without worsening steatohepatitis in patients with metabolic dysfunction-associated steatohepatitis compared to 22.5% in the placebo group.

The subcutaneous form of Leqembi was previously granted Fast Track designation by the FDA to treat mild cognitive impairment or mild dementia associated with Alzheimer disease based on data from the Clarity AD study.

In today’s pharmaceutical market access landscape, payers are not the sole decision-makers in utilization management development.

The latest news for pharma industry insiders.

Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab discussed how the use of Real-World Data has evolved in the healthcare industry in terms of privacy and targeting effectiveness.

The deal is expected to leverage EvolveImmune's T-cell engager EVOLVE platform to develop novel antibody-based therapies for solid and hematologic malignancies.

Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab explored how healthcare advertisers have been able to effectively target patients without relying heavily on traditional tracking methods.

The latest news for pharma industry insiders.

The executive director of patient strategies & solutions discusses J&J’s new Guide to Expanded Access.

The trials will investigate datopotamab deruxtecan in combination with treatments including rilvegostomig, osimertinib, and chemotherapy in patients with nonsquamous non-small cell lung cancer.

Accelerated approval is based on results of the ASC4FIRST Phase III trial, which demonstrated Scemblix's superior efficacy in achieving major molecular response compared to standard of care tyrosine kinase inhibitors in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding explore solutions for the current supply chain challenges and improve patient access to medications.

The alliance’s president discusses the current state of data sharing, security concerns, and the adoption AI.

The latest news for pharma industry insiders.

By demonstrating big advancements in recycling, pharma companies will be much more likely to attract shareholders and other investors, giving themselves a leg up in the competition to lead the biopharmaceutical industry well into the future.